Hovione stands behind 3 NCE launches

Hovione's commitment to supporting the high risk business of drug development is paying off.

FDA inspects Hovione's API manufacturing plant in Macau

Hovione's active pharmaceutical ingredients plant in Macau underwent a pre-approval inspection by FDA

Hovione consolidates API expertise to provide advanced technologies in particle design

Hovione is expanding its scientific know-how and industrial production capabilities on a variety of technologies to widen its ability to provide customized solutions for advanced APIs (aAPI™).

Hovione Group sales grow 9% to reach USD75 million for the fiscal year 2003/04

Hovione announces that the consolidated sales volume for the fiscal year ended 31st March 2004 amounted to US$75m, representing a growth of 9% over the previous year.

Hovione and CyDex announce drug development alliance for six potential new products

Hovione and CyDex, today announced an alliance to develop and commercialize improved formulations of drugs that are off-patent or soon will be off-patent.

Hovione launches new Particle Design technology and state-of-the-art Spray Drying facilities

Hovione is pleased to announce that it has installed a new state-of-the-art Spray Drying facility to address the latest technology in particle design.

The APIs supply chain: A case study

Carla Vozone and Manuel Lourenço look at Simvastatin as a case study in the supply of off-patent API

Hovione generic product portfolio update

Press Release, 15 September 2003

Hovione Group financial results for the year ended 31st March 2003

Hovione announces that sales for the year ended 31st March 2003 amounted to US$70m.

Ivan Villax, 1925-2003